Lyra Therapeutics (LYRA) Depreciation & Amortization (CF) (2019 - 2025)
Quarterly Depreciation & Amortization (CF) fell 65.5% to $59000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $459000.0 through Dec 2025, down 19.61% year-over-year, with the annual reading at $459000.0 for FY2025, 2.55% down from the prior year.
Lyra Therapeutics' Depreciation & Amortization (CF) history spans 7 years, with the latest figure at $59000.0 for Q4 2025.
- Depreciation & Amortization (CF) came in at $59000.0 for Q4 2025, down from $100000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $400000.0 in Q3 2021 to a low of -$68000.0 in Q3 2023.
- The 5-year median for Depreciation & Amortization (CF) is $185500.0 (2024), against an average of $175650.0.
- Year-over-year, Depreciation & Amortization (CF) surged 2207.69% in 2021 and then plummeted 122.67% in 2023.
- Lyra Therapeutics' Depreciation & Amortization (CF) stood at $278000.0 in 2021, then dropped by 8.27% to $255000.0 in 2022, then crashed by 58.04% to $107000.0 in 2023, then surged by 59.81% to $171000.0 in 2024, then plummeted by 65.5% to $59000.0 in 2025.
- Per Business Quant, the three most recent readings for LYRA's Depreciation & Amortization (CF) are $59000.0 (Q4 2025), $100000.0 (Q3 2025), and $200000.0 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 55.90 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 123.20 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 13.55 Mn |
| 10 | Lyra Therapeutics | - | - | - | 59,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 59,000.00 |
| Dec 31, 2025 | 59,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 200,000.00 |
| Jun 30, 2025 | 200,000.00 |
| Mar 31, 2025 | 100,000.00 |
| Mar 31, 2025 | 100,000.00 |
| Dec 31, 2024 | 171,000.00 |
| Dec 31, 2024 | 171,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 200,000.00 |
| Jun 30, 2024 | 200,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Dec 31, 2023 | 107,000.00 |
| Dec 31, 2023 | 107,000.00 |
| Sep 30, 2023 | -68,000.00 |
| Sep 30, 2023 | -68,000.00 |
| Jun 30, 2023 | -23,000.00 |
| Jun 30, 2023 | -23,000.00 |
| Mar 31, 2023 | 284,000.00 |
| Mar 31, 2023 | 284,000.00 |
| Dec 31, 2022 | 255,000.00 |
| Dec 31, 2022 | 255,000.00 |
| Sep 30, 2022 | 300,000.00 |
| Sep 30, 2022 | 300,000.00 |
| Jun 30, 2022 | 300,000.00 |
| Jun 30, 2022 | 300,000.00 |
| Mar 31, 2022 | 280,000.00 |
| Mar 31, 2022 | 280,000.00 |
| Dec 31, 2021 | 278,000.00 |
| Dec 31, 2021 | 278,000.00 |
| Sep 30, 2021 | 400,000.00 |
| Sep 30, 2021 | 400,000.00 |
| Jun 30, 2021 | 300,000.00 |
| Jun 30, 2021 | 300,000.00 |
| Mar 31, 2021 | 70,000.00 |
| Mar 31, 2021 | 70,000.00 |
| Dec 31, 2020 | 46,000.00 |
| Dec 31, 2020 | 46,000.00 |
| Sep 30, 2020 | 33,000.00 |
| Sep 30, 2020 | 33,000.00 |
| Jun 30, 2020 | 13,000.00 |
| Jun 30, 2020 | 13,000.00 |
| Mar 31, 2020 | 8,000.00 |
| Mar 31, 2020 | 8,000.00 |
| Dec 31, 2019 | 7,000.00 |
| Dec 31, 2019 | 7,000.00 |
| Sep 30, 2019 | 6,000.00 |
| Sep 30, 2019 | 6,000.00 |
| Jun 30, 2019 | 6,000.00 |
| Jun 30, 2019 | 6,000.00 |
| Mar 31, 2019 | 8,000.00 |
| Mar 31, 2019 | 8,000.00 |